# Long-term Administration Study of SND 919 Tablets in Parkinson's Disease

> **NCT00274131** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 170 (—)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Pramipexole 0.125 mg tablets
- **DRUG:** Pramipexole 0.5 mg tablets

## Key facts

- **NCT ID:** NCT00274131
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-12
- **Primary completion:** —
- **Final completion:** 2004-02
- **Target enrollment:** 170 (—)
- **Last updated:** 2012-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00274131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00274131, "Long-term Administration Study of SND 919 Tablets in Parkinson's Disease". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00274131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*